XBiotech Announces Enrollment Completion, Positive Findings for Bermekimab in Pancreatic Cancer Study

    NEXT STORY
    Progenics Pharmaceuticals Sets First Quarter 2019 Financial Results and Business Update Call for May 9
    PREV STORY
    Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses

    author_avatar
    NASDAQ Market News

    Adverum Biotechnologies Appoints Katherine Bock as Vice President, Investor Relations & Corporate Communications

    MENLO PARK, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a ...

    author_avatar
    NASDAQ Market News

    Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics

    author_avatar
    NASDAQ Market News